Home › NCT06832878
Postoperative Oral Tranexamic Acid in Patients Undergoing Primary Total Joint Arthroplasty
RecruitingPhase 4
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria * Adults aged \> 18 years (All women of childbearing potential undergo pregnancy testing prior to THA as per our institutional protocol) * Written informed consent * Patients undergoing primary THA diagnosis of end-stage osteoarthritis * Patients receiving spinal anesthesia * Patients being discharged on postoperative day 1 Exclusion Criteria * Patients with a TXA allergy * Patients undergoing revision procedures * Patients undergoing primary THA for a diagnosis other than end-stage osteoarthritis * Patients receiving general anesthesia * Patients being discharged on the same day of surgery * Cancer patients * Patients with a history of prior VTE event * Patients on preoperative anticoagulants other than ASA * Pregnant patients (All women of child bearing potential undergo pregnancy testing prior to THA as per our institutional protocol) * Female patients who are on hormonal contraception * Patients with history of retinal vein or artery occlusion
About the study
The purpose of this study is to evaluate the impact of an extended oral Tranexamic Acid regimen on patient reported outcome scores, time to independent ambulation, postoperative range of motion, swelling, change in hemoglobin levels, 90-day complications, readmission and reoperation.
What is being tested
- Oral Tranexamic Acid (drug)
Sponsor: Mayo Clinic · Participants: 101 · Started: Jun 1, 2026
Contact the study team
Official record on ClinicalTrials.gov — NCT06832878
Locations in the U.S.
| Arizona | Mayo Clinic in Arizona, Scottsdale |
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.